EN | UA
EN | UA

Help Support

Back

Study assesses efficacy and safety of Bulevirtide + Tenofovir disoproxil fumarate in hepatitis

hepatitis B virus and hepatitis D virus coinfection hepatitis B virus and hepatitis D virus coinfection
hepatitis B virus and hepatitis D virus coinfection hepatitis B virus and hepatitis D virus coinfection

What's new?

Over the course of 24 weeks, Bulevirtide caused a significant decrease in hepatitis D viral RNA.

In patients chronically infected with hepatitis D virus and hepatitis B virus (HBV), the use of Bulevirtide in combination with Tenofovir disoproxil fumarate (TDF) was associated with a significant decrease in hepatitis D virus RNA over 24 weeks. In this multicenter, randomized, parallel-group, open-label, phase 2 study (MYR202), Heiner Wedemeyer et al. examined the antiviral effect of Bulevirtide in individuals with hepatitis D virus and HBV coinfection.

Adults aged 18 to 65 years of age with chronic hepatitis D virus infection, encompassing those with cirrhosis, who were ineligible for pegylated-interferon-α (PegIFNα) therapy, or for whom treatment was unsuccessful, were recruited. Subjects were randomized (1:1:1:1) to get either TDF alone orally (245 mg once daily; n=30) or TDF plus 2 mg (n=28), 5 mg (n=32), or 10 mg (n=30) Bulevirtide once a day subcutaneously for 24 weeks.

A digital block technique with stratification was used for randomization, with 480 randomization numbers divided into 30 blocks. The key outcome, evaluated in modified intention-to-treat population which included people who were given investigational medicine at least once post-randomization, was undetectable hepatitis D virus RNA or a 2 log10 IU/mL or greater drop in hepatitis D virus RNA at 24th week. Until week 48, hepatitis D virus RNA levels were monitored. All subjects who got Bulevirtide or TDF at least once had their safety evaluated.

Overall, 120 individuals (59 of whom had cirrhosis) were included after a total of 171 subjects with chronic hepatitis D virus infection were screened. At week 24, 15 (54%) of 28 subjects treated with 2 mg of Bulevirtide, 16 (50%) of 32 treated with 5 mg of Bulevirtide, and 23 (77%) of 30 treated with 10 mg of Bulevirtide attained undetectable hepatitis D virus RNA or a 2 log10 IU/mL or higher decrease in hepatitis D virus RNA when compared to 1 (4%) of 28 with TDF only.

Hepatitis D virus RNA levels were reported to rebound by 48th week (24 weeks following Bulevirtide termination), with the median alterations from week 24 to week 48 of 1.923 log10 IU/mL (IQR 0.566-2.485) with 2 mg of Bulevirtide, 1.732 log10 (0.469-2.568) with 5 mg of Bulevirtide, and 2.030 log10 (1.262-2.903) with 10 mg of Bulevirtide. No fatalities related to the therapy were witnessed. Serious side effects occurred in 9% (n = 3) patients receiving 5 mg Bulevirtide, 7% (n = 2) patients receiving 10 mg Bulevirtide, and 4% (n = 1) patient receiving TDF. Elevation in alanine aminotransferase, aspartate aminotransferase, and asymptomatic bile salt levels were common treatment-emergent adverse effects.

Thus, Bulevirtide, a first-in-class peptidic entry suppressor for HBV and hepatitis D virus infection, caused a significant decrease in hepatitis D viral RNA. However, hepatitis D virus RNA levels rebounded after Bulevirtide cessation.

Source:

The Lancet Infectious Diseases

Article:

Safety and efficacy of Bulevirtide in combination with Tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial

Authors:

Heiner Wedemeyer et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: